-
平臺編號：bio-68383
-
國際編號：CRL-2265?
-
細(xì)胞信息： CEM/C1
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
CEM/C1
數(shù)量：大量
生長狀態(tài)：懸浮生長
運(yùn)輸方式：凍存運(yùn)輸
年限：4 years
細(xì)胞形態(tài)：淋巴樣
器官來源：外周血
細(xì)胞類型：T淋巴細(xì)胞
ATCC Number：CRL-2265?
相關(guān)疾病：白血病
是否是腫瘤細(xì)胞：0
物種來源：人
規(guī)格：0.1ml Designations: CEM/C1
Depositors: ?WG Harker
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Homo sapiens
Morphology:lymphoblast
Source: Organ: peripheral blood
Disease: acute lymphoblastic leukemia
Cell Type: T lymphoblast;
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Age: 4 years
Gender: female
Ethnicity: Caucasian
Comments:CEM/C1 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119 ).
The cell line was selected and subcloned in 1991 for resistance to CPT.
The cells exhibit cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT.
CEM/C1 cells are approximately 31 fold less sensitive to CPT than the parental CEM cells.
CEM/C1 cells display atypical multidrug resistance (MDR) and altered topoisomerase I catalytic activity.
Resistance to CPT is stable for up to six months.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of medium. Establish new cultures at 2 X 10 exp5 viable cells/ml and maintain between 1 X 10 exp5 and 2 X 10 exp6.
Preservation: culture medium 95%; DMSO, 5%
Doubling Time: 26 hrs
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
parental cell line:ATCC CCL-119
References: 22339: Kapoor R, et al. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7: 83-95, 1995. PubMed: 7579731
23117: Fujimori A, et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55: 1339-1346, 1995. PubMed: 7882333
生長狀態(tài)：懸浮生長
運(yùn)輸方式：凍存運(yùn)輸
年限：4 years
細(xì)胞形態(tài)：淋巴樣
器官來源：外周血
細(xì)胞類型：T淋巴細(xì)胞
ATCC Number：CRL-2265?
相關(guān)疾病：白血病
是否是腫瘤細(xì)胞：0
物種來源：人
規(guī)格：0.1ml Designations: CEM/C1
Depositors: ?WG Harker
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension
Organism: Homo sapiens
Morphology:lymphoblast
Source: Organ: peripheral blood
Disease: acute lymphoblastic leukemia
Cell Type: T lymphoblast;
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Age: 4 years
Gender: female
Ethnicity: Caucasian
Comments:CEM/C1 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119 ).
The cell line was selected and subcloned in 1991 for resistance to CPT.
The cells exhibit cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT.
CEM/C1 cells are approximately 31 fold less sensitive to CPT than the parental CEM cells.
CEM/C1 cells display atypical multidrug resistance (MDR) and altered topoisomerase I catalytic activity.
Resistance to CPT is stable for up to six months.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of medium. Establish new cultures at 2 X 10 exp5 viable cells/ml and maintain between 1 X 10 exp5 and 2 X 10 exp6.
Preservation: culture medium 95%; DMSO, 5%
Doubling Time: 26 hrs
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
parental cell line:ATCC CCL-119
References: 22339: Kapoor R, et al. Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin. Oncol. Res. 7: 83-95, 1995. PubMed: 7579731
23117: Fujimori A, et al. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 55: 1339-1346, 1995. PubMed: 7882333
